Executive function deficits in children with attention-deficit/ hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study

Atilla Turgay, Lawrence Ginsberg, Elias Sarkis, Rakesh Jain, Ben Adeyi, Joseph Gao, Bryan Dirks, Thomas Babcock, Brian Scheckner, Cynthia Richards, Robert Lasser, Robert L. Findling

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To assess the effects of lisdexamfetamine dimesylate (LDX) on executive function (EF) behaviors in children with attention-deficit/ hyperactivity disorder (ADHD). Methods: This observational, open-label, 7-week, dose-optimization study of LDX (20-70mg/day) in children with ADHD evaluated efficacy with the ADHD Rating Scale IV; safety measures included adverse events (AEs). EF was assessed with the Behavior Rating Inventory of Executive Function (BRIEF). Post hoc analyses examined BRIEF scores by sex, ADHD subtype, comorbid psychiatric symptoms, and common treatment-emergent AEs (TEAEs). ADHD Rating Scale IV scores were assessed in subjects categorized by baseline BRIEF global executive composite T scores with clinically significant (≥65) or not clinically significant (<65) impairment in EF. Results: Mean (standard deviation) change from baseline to endpoint for BRIEF of-17.9 (12.5) for Global Executive Composite,-15.4 (12.6) for Behavioral Regulation Index, and-17.6 (12.3) for Metacognition Index demonstrated improvement with LDX (pooled doses; p<0.0001 for all). Improvements in BRIEF scores were seen regardless of sex, ADHD subtype, comorbid psychiatric symptoms, common TEAEs, or baseline EF impairment category. TEAEs included decreased appetite, decreased weight, irritability, insomnia, headache, upper abdominal pain, and initial insomnia. Conclusions: Improvements were demonstrated in EF behaviors and ADHD symptoms with LDX. LDX safety profile was consistent with long-acting stimulant use.

Original languageEnglish (US)
Pages (from-to)503-511
Number of pages9
JournalJournal of child and adolescent psychopharmacology
Volume20
Issue number6
DOIs
StatePublished - Dec 1 2010
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Executive function deficits in children with attention-deficit/ hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study'. Together they form a unique fingerprint.

Cite this